Chronic myeloid leukemia: molecular monitoring in clinical practice.
about
Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsMolecular mechanisms of acquired resistance to tyrosine kinase targeted therapySAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells.Interpretation of cytogenetic and molecular results in patients treated for CML.Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors.Major molecular response in CML patients treated with tyrosine kinase inhibitors: the paradigm for monitoring targeted cancer therapyLong-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Current practices in the management of chronic myeloid leukemia.Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.Abl tyrosine kinase inhibitors for overriding Bcr-Abl/T315I: from the second to third generation.First-line therapy for chronic myeloid leukemia: Past, present, and future.Targeted therapy in haematological malignancies.Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.A longitudinal evaluation of performance of automated BCR-ABL1 quantitation using cartridge-based detection system.Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia.The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor eraRole of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.
P2860
Q27028181-255F7EF4-DA6A-4B13-813C-82EAA6E44E89Q33828409-B446FFE2-0325-4858-923B-84A7D772BD3BQ33911230-88313414-CC1B-4B44-800E-F97ACB59E174Q34765448-B5B29067-74C6-4277-96C3-D233CD9A445EQ35132293-38324F18-1E9B-4145-AD07-526AEB449127Q35584176-85713F28-1F95-41A7-AD8B-63C2E077B1FFQ35694453-022D56DD-A968-430D-9C2A-DB79B54DA258Q36819555-1C910F42-3F36-44B2-9D35-50DEAB5071EEQ37028631-5C674B94-25BC-41DD-A133-DDDF1F39BA0EQ37256808-FF6669AF-0503-49D6-B3CA-E68C6F805B97Q37420648-6865B75F-FC57-4E1F-81C9-525918110E39Q37664687-C0735988-9670-467A-9727-1274214B05EEQ39630966-C8718848-380D-414D-B089-C133F623F8F7Q41312327-535D239E-C33E-4618-BEE0-02287F808E9AQ41335233-1F5076B4-FBD1-4750-B472-E22BA1E53692Q41673629-CDE3812F-BBD2-4010-B785-B7C1594813ACQ42588031-887A6470-62F3-463D-915D-FF384E17DBADQ47290500-760D58F5-CD3F-4212-8515-3C3ECA5422C7
P2860
Chronic myeloid leukemia: molecular monitoring in clinical practice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chronic myeloid leukemia: molecular monitoring in clinical practice.
@en
Chronic myeloid leukemia: molecular monitoring in clinical practice.
@nl
type
label
Chronic myeloid leukemia: molecular monitoring in clinical practice.
@en
Chronic myeloid leukemia: molecular monitoring in clinical practice.
@nl
prefLabel
Chronic myeloid leukemia: molecular monitoring in clinical practice.
@en
Chronic myeloid leukemia: molecular monitoring in clinical practice.
@nl
P1476
Chronic myeloid leukemia: molecular monitoring in clinical practice.
@en
P2093
Susan Branford
P304
P356
10.1182/ASHEDUCATION-2007.1.376
P577
2007-01-01T00:00:00Z